Screening for abnormal placentation and adverse pregnancy outcomes with maternal serum biomarkers in the second trimester

Katherine R. Goetzinger, Anthony O. Odibo

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations

Abstract

Second trimester biomarkers were initially introduced with the intent of screening for neural tube defects and then subsequently for Down syndrome. It was soon realized that these markers can be indirect evidence of abnormal placentation and, therefore, can be used for screening for adverse pregnancy outcomes. Several new biomarkers have subsequently been described with conflicting findings regarding their efficiency for screening for adverse pregnancy outcomes. Although a biologically feasible mechanism has been proposed for the role of these biomarkers, they still fall short of an ideal screening test to be clinically useful.

Original languageEnglish
Pages (from-to)635-641
Number of pages7
JournalPrenatal Diagnosis
Volume34
Issue number7
DOIs
StatePublished - Jul 1 2014

Fingerprint

Dive into the research topics of 'Screening for abnormal placentation and adverse pregnancy outcomes with maternal serum biomarkers in the second trimester'. Together they form a unique fingerprint.

Cite this